Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AACR Cancer Progress Report 2013.
AACR Cancer Progress Report Writing Committee; Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ. AACR Cancer Progress Report Writing Committee, et al. Among authors: anderson kc. Clin Cancer Res. 2013 Oct 15;19(20 Suppl):S4-98. doi: 10.1158/1078-0432.CCR-13-2107. Epub 2013 Sep 16. Clin Cancer Res. 2013. PMID: 24045178 No abstract available.
Introducing the clinical connection.
Anderson KC. Anderson KC. Clin Cancer Res. 2007 Jul 1;13(13):3761. doi: 10.1158/1078-0432.CCR-07-1410. Clin Cancer Res. 2007. PMID: 17606703 No abstract available.
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.
Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell TB, Kaiser S, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje NS. Waldschmidt JM, et al. Among authors: anderson kc. Blood Adv. 2025 Jan 15:bloodadvances.2024015285. doi: 10.1182/bloodadvances.2024015285. Online ahead of print. Blood Adv. 2025. PMID: 39813623
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Nadeem O, et al. Among authors: anderson kc. Nat Commun. 2025 Jan 3;16(1):358. doi: 10.1038/s41467-024-55308-5. Nat Commun. 2025. PMID: 39753553 Free PMC article. Clinical Trial.
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell E, Bianchi G, Branagan AR, Schlossman RL, Shaprio SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd RA, Lohr JG, Anderson KC, Richardson PG, Raje N. Yee AJ, et al. Among authors: anderson kc. Blood Adv. 2024 Dec 3:bloodadvances.2024014717. doi: 10.1182/bloodadvances.2024014717. Online ahead of print. Blood Adv. 2024. PMID: 39626297
Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.
Donnelly RS, Cavallari LH, McCune JS, Trofe-Clark J, Formea CM, Hoffecker G, Csere MM, Anderson KC, Bhat S, Mosley SA, Ma Q, Ferdock A, Hoffman JM, Hicks JK, Caudle KE. Donnelly RS, et al. Among authors: anderson kc. J Am Coll Clin Pharm. 2024 Jun;7(6):581-588. doi: 10.1002/jac5.1958. Epub 2024 May 8. J Am Coll Clin Pharm. 2024. PMID: 39582510
1,229 results